Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Cantor Fitzgerald

Generated: September 16, 2019

DrugPatentWatch Database Preview

Patent: 10,280,468

  Try a free trial

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,280,468
Title:Molecular diagnostic test for predicting response to anti-angiogenic drugs and prognosis of cancer
Abstract: Methods for selecting whether to administer an anti-angiogenic therapeutic agent to a subject include steps of measuring the expression levels of one or more biomarkers selected from Table 2 or Table 3 in a sample from the subject; assessing from the expression levels of the one or more biomarkers whether the sample from the subject is positive or negative for a biomarker signature, wherein if the sample is positive for the biomarker signature an anti-angiogenic therapeutic agent is contraindicated. Related prognostic methods and treatment methods are also provided. The invention is particularly applicable in ovarian and colorectal cancers.
Inventor(s): Harkin; Denis Paul (Dromore, GB), Kennedy; Richard (Belfast, GB), Keating; Katherine E. (Magherafelt, GB), McCavigan; Andrena (Derryadd Lurgan, GB), Hill; Laura A. (Lisburn, GB), Deharo; Steve (Belfast, GB), Davison; Timothy (Hillsborough, GB), Patterson; Fionnuala (Hauxton, GB), Donegan; Sinead (Belfast, GB), Jellema; Gera (Portadown, GB), Gourley; Charlie (Dumfermline, GB)
Assignee: Almac Diagnostics Limited (Craigavon, GB)
Application Number:15/116,641
Patent Claims:see list of patent claims

Details for Patent 10,280,468

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Try a Free Trial Almac Diagnostics Limited (Craigavon, GB) 2034-05-28 RX search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Try a Free Trial Almac Diagnostics Limited (Craigavon, GB) 2034-05-28 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.